Literature DB >> 21160410

HIV-1 infection and cognitive impairment in the cART era: a review.

Judith Schouten, Paola Cinque, Magnus Gisslen, Peter Reiss, Peter Portegies.   

Abstract

With the introduction of combination antiretroviral therapy AIDS dementia complex or HIV-associated dementia, as it was termed later, largely disappeared in clinical practice. However, in the past few years, patients, long-term infected and treated, including those with systemically well controlled infection, started to complain about milder memory problems and slowness, difficulties in concentration, planning, and multitasking. Neuropsychological studies have confirmed that cognitive impairment occurs in a substantial (15-50%) proportion of patients. Among HIV-1-infected patients cognitive impairment was and is one of the most feared complications of HIV-1 infection. In addition, neurocognitive impairment may affect adherence to treatment and ultimately result in increased morbidity for systemic disease. So what may be going on in the CNS after so many years of apparently controlled HIV-1 infection is an urgent and important challenge in the field of HIV medicine. In this review we summarize the key currently available data. We describe the clinical neurological and neuropsychological findings, the preferred diagnostic approach with new imaging techniques and cerebrospinal fluid analysis. We try to integrate data on pathogenesis and finally discuss possible therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21160410     DOI: 10.1097/QAD.0b013e3283437f9a

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  110 in total

1.  Role of Macrophage Dopamine Receptors in Mediating Cytokine Production: Implications for Neuroinflammation in the Context of HIV-Associated Neurocognitive Disorders.

Authors:  R A Nolan; R Muir; K Runner; E K Haddad; P J Gaskill
Journal:  J Neuroimmune Pharmacol       Date:  2018-12-05       Impact factor: 4.147

2.  Modeling a Theory-Based Approach to Examine the Influence of Neurocognitive Impairment on HIV Risk Reduction Behaviors Among Drug Users in Treatment.

Authors:  Tania B Huedo-Medina; Roman Shrestha; Michael Copenhaver
Journal:  AIDS Behav       Date:  2016-08

Review 3.  Neurocognitive impact of antiretroviral treatment: thinking long-term.

Authors:  Megan E McPhail; Kevin R Robertson
Journal:  Curr HIV/AIDS Rep       Date:  2011-12       Impact factor: 5.071

4.  Nuclear-Mitochondrial interactions influence susceptibility to HIV-associated neurocognitive impairment.

Authors:  S Smieszek; P Jia; D C Samuels; Z Zhao; J Barnholtz-Sloan; H Kaur; S Letendre; R Ellis; D R Franklin; T Hulgan; A Kallianpur; W S Bush
Journal:  Mitochondrion       Date:  2018-07-17       Impact factor: 4.160

5.  Translational spatial task and its relationship to HIV-associated neurocognitive disorders and apolipoprotein E in HIV-seropositive women.

Authors:  Diana Morales; Summer F Acevedo; Richard L Skolasky; Rosa Hechavarria; Sharon Santiago; Tania De La Torre; Elizabeth Maldonado; Valerie Wojna
Journal:  J Neurovirol       Date:  2012-09-13       Impact factor: 2.643

6.  Cathepsin B and cystatin B in HIV-seropositive women are associated with infection and HIV-1-associated neurocognitive disorders.

Authors:  Yisel Cantres-Rosario; Marines Plaud-Valentín; Yamil Gerena; Richard L Skolasky; Valerie Wojna; Loyda M Meléndez
Journal:  AIDS       Date:  2013-01-28       Impact factor: 4.177

7.  Effect of ginkgo biloba on the pharmacokinetics of raltegravir in healthy volunteers.

Authors:  Maren Blonk; Angela Colbers; Anne Poirters; Bas Schouwenberg; David Burger
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

8.  The role of HIV infection, cognition, and depression in risky decision-making.

Authors:  April D Thames; Vanessa Streiff; Sapna M Patel; Stella E Panos; Steven A Castellon; Charles H Hinkin
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2012       Impact factor: 2.198

9.  Relationship of plasma cytokines and clinical biomarkers to memory performance in HIV.

Authors:  Stephen Correia; Ronald Cohen; Assawin Gongvatana; Skye Ross; James Olchowski; Kathryn Devlin; Karen Tashima; Bradford Navia; Suzanne Delamonte
Journal:  J Neuroimmunol       Date:  2013-09-27       Impact factor: 3.478

10.  The cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIV.

Authors:  Edward R Hammond; Rosa M Crum; Glenn J Treisman; Shruti H Mehta; Christina M Marra; David B Clifford; Susan Morgello; David M Simpson; Benjamin B Gelman; Ronald J Ellis; Igor Grant; Scott L Letendre; Justin C McArthur
Journal:  Am J Epidemiol       Date:  2014-06-24       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.